View : 95 Download: 0
Cutaneous T-cell lymphoma in Asian patients: a multinational, multicenter, prospective registry study in Asia
- Cutaneous T-cell lymphoma in Asian patients: a multinational, multicenter, prospective registry study in Asia
- Lee Y.-P.; Yoon S.E.; Song Y.; Kim S.J.; Yoon D.H.; Chen T.-Y.; Koh Y.I.; Kang K.W.; Lee H.; Wei K.T.K.; Lim S.T.; Poon M.; Irawan C.; Zhao W.; Do Y.R.; Lee M.H.; Ng S.C.; Lee W.-S.; Guo Y.; Zhang H.; Kang H.-J.; Yun H.J.; Kim H.J.; Lung D.T.C.; Kwak J.-Y.; Han J.J.; Mun Y.-C.; Oh S.Y.; Shim H.; Kwon J.H.; Sohn B.S.; Park S.K.; Jo J.C.; Ko Y.H.; Jun Z.; Kim W.S.
- Ewha Authors
- SCOPUS Author ID
- Issue Date
- Journal Title
- International Journal of Hematology
- International Journal of Hematology vol. 114, no. 3, pp. 355 - 362
- Cutaneous; Incidence; Lymphoma; Prognosis; Survival; T-cell; Therapeutics
- Springer Japan
- SCIE; SCOPUS
- Document Type
- Cutaneous T-cell lymphomas (CTCLs) are a group of T-cell lymphomas with low incidence. Due to their indolent characteristics, treatment strategies have not yet been established for advanced CTCLs. In this study, relative incidence of CTCLs in Asia was estimated and the therapeutic outcomes presented based on various treatments currently used in clinics for advanced CTCLs. As part of a prospective registry study of peripheral T-cell lymphoma (PTCL) conducted across Asia, including Korea, China, Taiwan, Singapore, Malaysia, and Indonesia, subgroup analysis was performed for patients with CTCLs. Among 486 patients with PTCL, 37 with CTCL (7.6%) were identified between April 2016 and February 2019. Primary cutaneous ALK-negative anaplastic large cell lymphoma (ALCL, 35.1%) was the most common subtype. With a median follow-up period of 32.1 months, median progression-free survival (PFS) was 53.5 months (95% CI 0.0–122.5), and overall survival was not reached. 14 patients (48.2%) underwent subsequent treatment after the first relapse, but the response rate was 20% with a PFS of 2.2 months (95% CI 0.3–4.0). Six patients received autologous stem cell transplantation (auto-SCT). However, auto-SCT did not result in better outcomes. Additional studies are needed on standard care treatment of advanced or refractory and relapsed CTCLs. © 2021, Japanese Society of Hematology.
- Appears in Collections:
- 의과대학 > 의학과 > Journal papers
- Files in This Item:
There are no files associated with this item.
- RIS (EndNote)
- XLS (Excel)
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.